Viamet Pharmaceuticals Secures $60,000,000 Series D Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=647fc483-5d57-4942-8954-18f506244152 - Date
10/21/2014 - Company Name
Viamet Pharmaceuticals - Mailing Address
4505 Emperor Blvd. Durham, NC 27703 USA - Company Description
Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology. - Website
http://www.viamet.com - Transaction Type
Venture Equity - Transaction Amount
$60,000,000 - Transaction Round
Series D - Proceeds Purposes
l compounds, as well as to initiate new research programs supported by the company’s Metallophile® platform. The financing is expected to provide sufficient capital to fund operations through the achievement of several important clinical milestones over the next number of years. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
